Compare Stocks → This consistently signaled gains of 453%... 610%... and even 1036%... (From Insiders Exposed) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADMPNYSE:ANVSNASDAQ:BLPHNASDAQ:EVOKNASDAQ:MBRX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMPAdamis Pharmaceuticals$1.28$0.75▼$26.18$7.26M1.27811,695 shs119,800 shsANVSAnnovis Bio$12.00-0.2%$10.19$5.42▼$23.89$126.96M1.55283,444 shs68,972 shsBLPHBellerophon Therapeutics$0.06-1.6%$0.06$0.03▼$12.58$695K0.6732,450 shs1,066 shsEVOKEvoke Pharma$0.62+5.9%$0.67$0.56▼$2.42$5.27M0.2163,356 shs8,655 shsMBRXMoleculin Biotech$5.52-0.4%$7.88$4.34▼$24.75$12.31M1.9830,295 shs20,677 shs10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMPAdamis Pharmaceuticals0.00%0.00%0.00%0.00%-90.37%ANVSAnnovis Bio+0.42%+7.80%+34.72%-38.91%-39.03%BLPHBellerophon Therapeutics-1.60%+11.18%+6.69%+67.10%-99.24%EVOKEvoke Pharma+0.05%+2.02%-3.95%-45.00%-71.46%MBRXMoleculin Biotech+18.38%-12.19%-37.29%-50.76%-61.11%The AI Defense Stock Set to Soar (Ad)To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.Here's how you can invest >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMPAdamis PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AANVSAnnovis Bio2.3736 of 5 stars3.43.00.00.02.91.70.6BLPHBellerophon Therapeutics1.8118 of 5 stars3.20.00.04.81.90.00.6EVOKEvoke PharmaN/AN/AN/AN/AN/AN/AN/AN/AMBRXMoleculin Biotech3.1026 of 5 stars3.55.00.00.03.00.01.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMPAdamis PharmaceuticalsN/AN/AN/AN/AANVSAnnovis Bio2.75Moderate Buy$27.75131.25% UpsideBLPHBellerophon Therapeutics2.33Hold$2.003,420.20% UpsideEVOKEvoke PharmaN/AN/AN/AN/AMBRXMoleculin Biotech3.00Buy$101.671,741.79% UpsideCurrent Analyst RatingsLatest ANVS, ADMP, MBRX, EVOK, and BLPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/26/2024MBRXMoleculin BiotechMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$45.00 ➝ $20.003/21/2024ANVSAnnovis BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.002/28/2024ANVSAnnovis BioBrookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$9.0012/29/2023ANVSAnnovis BioCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$36.0012/29/2023ANVSAnnovis BioCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$36.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMPAdamis Pharmaceuticals$4.76M0.00N/AN/A($1.26) per share0.00ANVSAnnovis BioN/AN/AN/AN/A$3.47 per shareN/ABLPHBellerophon TherapeuticsN/AN/AN/AN/A$0.27 per shareN/AEVOKEvoke Pharma$5.18M1.02N/AN/A($0.77) per share-0.81MBRXMoleculin BiotechN/AN/AN/AN/A$27.33 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMPAdamis Pharmaceuticals-$26.48MN/A0.00N/AN/A-502.73%-420.53%-256.87%N/AANVSAnnovis Bio-$25.33M-$4.27N/AN/AN/AN/A-195.55%-156.80%4/1/2024 (Estimated)BLPHBellerophon Therapeutics-$19.83M-$0.84N/A∞N/AN/A-187.35%-104.97%3/29/2024 (Estimated)EVOKEvoke Pharma-$7.79M-$2.33N/A∞N/A-150.43%-517.99%-91.83%5/20/2024 (Estimated)MBRXMoleculin Biotech-$29.77M-$13.64N/AN/AN/AN/A-80.91%-67.69%5/9/2024 (Estimated)Latest ANVS, ADMP, MBRX, EVOK, and BLPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/29/2024N/ABLPHBellerophon TherapeuticsN/A-$0.42-$0.42N/AN/AN/A3/14/2024Q4 2023EVOKEvoke PharmaN/A-$0.59-$0.59-$0.59N/A$1.68 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMPAdamis PharmaceuticalsN/AN/AN/AN/AN/AANVSAnnovis BioN/AN/AN/AN/AN/ABLPHBellerophon TherapeuticsN/AN/AN/AN/AN/AEVOKEvoke PharmaN/AN/AN/AN/AN/AMBRXMoleculin BiotechN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMPAdamis PharmaceuticalsN/A0.230.19ANVSAnnovis BioN/A2.872.87BLPHBellerophon TherapeuticsN/A3.963.96EVOKEvoke Pharma9.292.252.09MBRXMoleculin BiotechN/A3.867.10OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMPAdamis Pharmaceuticals38.55%ANVSAnnovis Bio15.83%BLPHBellerophon Therapeutics10.61%EVOKEvoke PharmaN/AMBRXMoleculin Biotech15.52%Insider OwnershipCompanyInsider OwnershipADMPAdamis Pharmaceuticals1.30%ANVSAnnovis Bio38.30%BLPHBellerophon Therapeutics5.20%EVOKEvoke Pharma11.78%MBRXMoleculin Biotech6.70%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADMPAdamis Pharmaceuticals119.36 million9.24 millionOptionableANVSAnnovis Bio510.58 million6.53 millionOptionableBLPHBellerophon Therapeutics1812.23 million11.60 millionOptionableEVOKEvoke Pharma48.48 million7.48 millionNot OptionableMBRXMoleculin Biotech152.23 million2.08 millionNot OptionableANVS, ADMP, MBRX, EVOK, and BLPH HeadlinesSourceHeadlineMoleculin to Present at the MedInvest Biotech & Pharma Investor Conferencefinance.yahoo.com - March 28 at 11:23 AMMoleculin Biotech (NASDAQ:MBRX) Receives New Coverage from Analysts at StockNews.comamericanbankingnews.com - March 28 at 3:34 AMEquities Analysts Set Expectations for Moleculin Biotech, Inc.'s FY2028 Earnings (NASDAQ:MBRX)americanbankingnews.com - March 28 at 1:36 AMMoleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AMLfinance.yahoo.com - March 27 at 1:35 PMMoleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunityprnewswire.com - March 27 at 9:25 AMMoleculin Biotech (NASDAQ:MBRX) Price Target Lowered to $20.00 at Maxim Groupamericanbankingnews.com - March 27 at 3:18 AMMoleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 26 at 9:48 AMNews - Moleculin Biotechthepharmaletter.com - March 25 at 11:47 PMMoleculin Biotech, Inc.: Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trialfinanznachrichten.de - March 25 at 6:45 PMMoleculin skyrockets on interim data for annamycin MB-106 trialthepharmaletter.com - March 25 at 6:45 PMMoleculin Biotech Reports Positive Interim Data From MB-106 Phase 1B/2 Study In AMLmarkets.businessinsider.com - March 25 at 9:05 AMMoleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trialfinance.yahoo.com - March 25 at 9:05 AMMoleculin Biotech, Inc.: Moleculin Reports Full Year 2023 Financial Resultsfinanznachrichten.de - March 23 at 10:20 AMMBRX Stock Earnings: Moleculin Biotech Reported Results for Q4 2023investorplace.com - March 22 at 10:03 PMMoleculin Biotech Inc Reports Fiscal Year 2023 Financial Resultsfinance.yahoo.com - March 22 at 7:18 PMMoleculin Reports Full Year 2023 Financial Resultsprnewswire.com - March 22 at 4:05 PMMoleculin Biotech announces 1-for-15 reverse stock splitinvesting.com - March 21 at 11:00 PMA Preview Of Moleculin Biotech's Earningsbenzinga.com - March 21 at 5:59 PMMoleculin Biotech, Inc.: Moleculin Announces Reverse Stock Splitfinanznachrichten.de - March 20 at 1:07 PMMoleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcastprnewswire.com - March 20 at 7:30 AMMoleculin Biotech (NASDAQ:MBRX) Earns Sell Rating from Analysts at StockNews.comamericanbankingnews.com - March 20 at 3:30 AMMoleculin Announces Reverse Stock Splitfinance.yahoo.com - March 19 at 9:29 PMMoleculin to Present at the 36th Annual ROTH Conferencefinance.yahoo.com - March 12 at 9:24 AMA new chapter for biotech: Confidence returns to the marketfiercebiotech.com - March 5 at 8:18 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAdamis PharmaceuticalsNASDAQ:ADMPAdamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.Annovis BioNYSE:ANVSAnnovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.Bellerophon TherapeuticsNASDAQ:BLPHBellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.Evoke PharmaNASDAQ:EVOKEvoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.Moleculin BiotechNASDAQ:MBRXMoleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It is also developing WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company was incorporated in 2015 and is headquartered in Houston, Texas. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.